Charles River Laboratorie (CRL) Misses Q2 EPS by 1c; Extends Agreement with AstraZeneca (AZN)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
Go back to Charles River Laboratorie (CRL) Misses Q2 EPS by 1c; Extends Agreement with AstraZeneca (AZN)
July 30, 2015 7:01 AM EDT
- Leading Global CRO and Global Biopharmaceutical Company Extend
Relationship to Accelerate Drug Development -
WILMINGTON, Mass.--(BUSINESS WIRE)--
Charles River Laboratories International, Inc. (NYSE: CRL) today
announced that it has extended its initial three-year partnership with
AstraZeneca (NYSE: AZN) for an additional five-year period. Under the
agreement, which extends into 2020, Charles River retains its position
as AstraZenecas preferred strategic partner for outsourced regulated
safety assessment and development DMPK (drug metabolism and
pharmacokinetics).
James C. Foster, Chairman,... More
July 30, 2015 7:00 AM EDT
Second-Quarter Revenue of $339.6 Million
Second-Quarter GAAP Earnings per Share of $1.02
and
Non-GAAP Earnings per Share of $0.96
Updates 2015 Guidance for Celsis Acquisition
Renews Strategic Partnership with AstraZeneca
Plans to Reopen Shrewsbury, Massachusetts Facility in Early 2016
WILMINGTON, Mass.--(BUSINESS WIRE)--
Charles River Laboratories International, Inc. (NYSE: CRL) today
reported its results for the second quarter of 2015. For the quarter,
revenue from continuing operations was $339.6 million, a decrease of
0.5% from $341.2 million in the second quarter of 2014. Foreign currency... More
